ARCHIVES

Phase III Trial Of PARP Inhibitor BSI-201 Opens For Triple-Negative Breast Cancer

This article is from The Cancer Letter archive.

Vol. 32 No. 7 | July 31, 2009

Download PDF Visit The Full Archive

Related Articles

Women 80 And Older Benefit From Mammography

May 30, 2008

Weak Structure, Deficiencies, Cited In Dana-Farber Reviews

November 3, 1995

Evidence Supports Screening Younger Women, Expert Says

September 24, 1993

In Brief: Forel Retires As Dana-Farber Director, Successor Is David Livingston; Benacerraf Plans Departure

July 5, 1991

Procedures For Ending IGs Announced

July 10, 1992

In Brief: Jensen, Selikoff Receive ACS National Awards; CCIRC Schedules Mini-Symposium

October 22, 1976